Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPORT: Reirradiation and nivolumab for recurrent head and neck squamous cell carcinoma
2016-005240-42Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Oslo University Hospital. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2016-005240-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005240-42.